NEUROONE MEDICAL TECHNOLOGIES Corp NMTC
Medical/Dental Instruments · data as of November 13, 2026
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $9M and net income of -$7M, a net margin of -78.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -251%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 2% below the current price.
About NEUROONE MEDICAL TECHNOLOGIES
NEUROONE MEDICAL TECHNOLOGIES is listed in the US and classified in medical/dental instruments. Revenue went from $773 in 2014 to $9M in 2025, growth of about 134.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 151% over three years (dilution for shareholders). It spends 55% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $9M | $3M | $2M | $171169 | $178146 | — | — | — | $0 | $0 |
| Net income | -$7M | -$4M | -$12M | -$12M | -$10M | -$10M | -$14M | -$7M | -$5M | -$47775 | -$62863 |
| Free cash flow | -$7M | -$3M | -$11M | -$13M | -$8M | -$9M | -$4M | -$5M | — | — | — |
| EPS (diluted) | $-0.36 | $-0.09 | $-0.46 | $-0.65 | $-0.63 | $-0.93 | $-2.52 | $-1.71 | $-2.31 | $-0.03 | $-0.03 |
| Net margin | -78.6% | -39.6% | -356.7% | -607.4% | -5841.9% | -5584.3% | — | — | — | — | — |
| ROIC | — | -45.5% | -867.8% | -145.6% | -80.5% | -116.0% | -108.1% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is NEUROONE MEDICAL TECHNOLOGIES stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 2% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does NEUROONE MEDICAL TECHNOLOGIES pay a dividend?
Not currently.
Is NEUROONE MEDICAL TECHNOLOGIES a good stock to buy?
We do not give buy or sell advice. NEUROONE MEDICAL TECHNOLOGIES scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.